|Brand name(s), other common name(s)||KyprolisTM|
|Drug type||Proteasome inhibitor|
|How the drug is given||Intravenously (IV)|
Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Side effects needing medical attention:Fatigue; anemia; nausea; low platelet counts; breathlessness; diarrhea; fever; cardiac arrest and other cardiac failure events; pulmonary hypertension; pulmonary complications; liver damage and liver failure; infusion reactions including fever, chills, joint pain, muscle pain, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, fainting, chest tightness, chest pain.